Venetoclax for the treatment of patients with chronic lymphocytic leukemia

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

(2017) John F Seymour et al.   LANCET ONCOLOGY

Therapeutic targeting of IL-7R  signaling pathways in ALL treatment

(2016) S. D. Cramer et al.   BLOOD

Platelet WDR1 suppresses platelet activity and is associated with cardiovascular disease

(2016) E. Montenont et al.   BLOOD

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

(2016) M. A. Anderson et al.   BLOOD

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

(2016) B. L. Lampson et al.   BLOOD

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor

(2016) Ahmed Hamed Salem et al.   JOURNAL OF CLINICAL PHARMACOLOGY

An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data

(2016)   LANCET ONCOLOGY

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

(2016) Stephan Stilgenbauer et al.   LANCET ONCOLOGY

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia

(2015) R. Guieze et al.   BLOOD

Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib

(2015) J. C. Byrd et al.   BLOOD

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

(2015) P. A. Thompson et al.   BLOOD

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

(2015) K. Fischer et al.   BLOOD

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

(2015) Peter Hillmen et al.   LANCET

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

(2015) Kami J. Maddocks et al.   JAMA Oncology

High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis

(2014) N. A. Brown et al.   BLOOD

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

(2014) Matthew S Davids et al.   Future Oncology

Chronic Lymphocytic Leukemia

(2014) Chadi Nabhan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia

(2012) M. S. Davids et al.   BLOOD

Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer

(2012) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

(2008) T. Zenz et al.   BLOOD